Versartis Inc. (Nasdaq: VSAR) reported disappointing results from a VELOCITY Phase 3 clinical trial of somavaratan to treat pediatric growth hormone deficiency. Shares of the biopharmaceutical collapsed $18.93 to close at $2.67.
Disappointing study results for Versartis
September 22, 2017 at 19:24 PM EDT
